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Background: Lung cancer is the leading cause of cancer death in North America and Western Europe. Patients
with lung cancer in general have reduced physical capacity, functional capacity, poor quality of life and increased
levels of anxiety and depression. Intervention studies indicate that physical training can address these issues.
However, there is a lack of decisive evidence regarding the effect of physical exercise in patients with advanced
lung cancer. The aim of this study is to evaluate the effects of a twelve weeks, twice weekly program consisting of:
supervised, structured training in a group of advanced lung cancer patients (cardiovascular and strength training,
relaxation).
Methods/Design: A randomized controlled trial will test the effects of the exercise intervention in 216 patients
with advanced lung cancer (non-small cell lung cancer (NSCLC) stage IIIb - IV and small cell lung cancer (SCLC)
extensive disease (ED)). Primary outcome is maximal oxygen uptake (VO2peak). Secondary outcomes are muscle
strength (1RM), functional capacity (6MWD), lung capacity (Fev1) and patient reported outcome (including anxiety,
depression (HADS) and quality of life (HRQOL)).
Discussion: The present randomized controlled study will provide data on the effectiveness of a supervised
exercise intervention in patients receiving systemic therapy for advanced lung cancer. It is hoped that the
intervention can improve physical capacity and functional level, during rehabilitation of cancer patients with
complex symptom burden and help them to maintain independent function for as long as possible.
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Lung cancer is the leading cause of cancer death in North
America and Western Europe [1]. In Denmark, the rela-
tive survival 1, 3 and 5 years after diagnosis of lung cancer
is 32%, 13% and 10%, respectively. The best prognosis is
achieved for patients who have lung cancer at an early
stage (Non-small Cell Lung Cancer (NSCLC) stage I-IIIa
and Small Cell Lung Cancer (SCLC) limited disease (LD))
and are receiving treatment with curative intent. For pa-
tients with advanced lung cancer (NSCLC IIIb-IV SCLC
ED), the median survival after diagnosis is 10–13 months
[2]. Despite improved treatment methods with surgery,
chemotherapy, biological therapy and radiotherapy and
more focus on supportive therapy, survival has not chan-
ged significantly over the last 10 years [3].
Patients with lung cancer receiving chemotherapy often
experience a range of treatment- and disease-related symp-
toms such as dyspnea, cough, pain, decreased appetite, de-
creased functional capacity, and fatigue [4]. A comparison
of quality of life (HRQOL) in treated lung cancer patients
with other treated cancer patients indicates that patients
with lung cancer in particular are suffering from several
physical and psychosocial problems [5-7]. A Danish study
highlighted physical, psychological and social problems
among cancer patients with a broad spectrum of diagnoses.
The results showed that lung cancer patients had more
symptoms and side effects, increased anxiety and depres-
sion levels and impaired HRQOL compared to patients
with 10 other cancer diagnoses [8]. Patients with meta-
static, incurable tumors, such as lung and pancreatic can-
cer, reported the heaviest symptom and side effect burden
compared with other cancer diagnoses [9].
It is well documented that physical activity can relieve
symptoms and side effects in selected groups of cancer pa-
tients, including fatigue, cachexia and depression [10-15].
The benefits of physical activity for cancer patients have
been described in several studies [16-21]. The majority of
these studies include patients with breast cancer, prostate
cancer and haematological malignancies. These studies
have primarily measured the physical, functional capacity
and HRQOL and predominantly included patient groups
with relatively low disease burden.
In 2006 [22], our group demonstrated in a non-
randomized study that 6 weeks of intervention with
physical training (4× weekly) was beneficial to cancer
patients with different diagnoses, both in early and in ad-
vanced stages. Patients increased their muscle strength
(1RM) by 41% and V02max by 14.5%. The effect of this
intervention was confirmed in a randomized controlled
study from 2009 [23], where in addition to an increase in
muscle strength and V02max, patients also reported a
clinical significant reduction in fatigue. The study in-
cluded 269 patients with different diagnoses, with few
patients having lung cancer (n = 10). Analyses showedthat lung cancer patients receiving chemotherapy indi-
cated the same (percentage) physical progress as other
cancer patients. However, lung cancer patients had sig-
nificantly lower VO2max at baseline compared to other
diagnostic groups (lung VO2max baseline = 1.15 L/min
vs. other diagnoses baseline 2.27 L/min). Moreover, the
lung cancer patients indicated that the exercise intensity
(4 times per week) was too strenuous.
The existing knowledge about the effects of physical
activity for lung cancer patients with advanced disease is
sparse. The majority [24-28] of the studies that have
tested aerobic training have been performed on lung
cancer patients in an early stage of disease (NSCLC I-II
LD SCLC) who did not receive chemotherapy and/or
radiotherapy. The studies showed significant successes
with regard to HRQOL and physical function (6 MWD)
and physical capacity (VO2peak and 1RM) but have in-
cluded relatively few patients (N = 10–23). Three studies
have included patients with advanced inoperable lung
cancer receiving chemotherapy [29-31]. Temel et al. [30]
studied the effect of an eight-week (2 × weekly) training
(fitness and strength) on 25 patients with lung cancer
(NSCLC stage IIIb - IV), of which 18 patients received
chemotherapy. The results showed no significant improve-
ment in quality of life, anxiety or depression as measured
by Functional Assessment of Cancer Therapy - Lung
(FACT-L) and Hospital Anxiety and Depression scale
(HAD). The physiological results showed a significant in-
crease in strength of a single muscle group. There was no
significant progress in the functional walk test (6MWD).
Other studies have shown that physical exercise and relax-
ation techniques can relieve side effects and symptoms in
cancer patients with advanced disease receiving chemo-
therapy [23,32,33].
In a pilot study from 2011 [29], our group showed that
advanced (inoperable) lung cancer patients (NSCLC
IIIb-IV SCLC ED) in chemotherapy could increase their
exercise capacity (fitness, strength), functional capacity
(6MWD) and emotional well-being (FACT-L) in a phys-
ical intervention (supervised and home exercises) two
times weekly for 6 weeks. Patients reported no change
in HRQOL. This study also showed that this interven-
tion was feasible and safe for inoperable lung cancer
patients receiving chemotherapy. Home training in
addition to the supervised training was not feasible due
to lack of compliance [34].
According to published data, patients with lung cancer
in general have reduced physical capacity, functional
capacity, poor quality of life and increased levels of anx-
iety and depression. Intervention studies indicate that
physical training can address these issues in lung cancer
patients with low stage (I-IIIa). We and others have
shown that physical exercise for lung cancer patients
with advanced stage (IIIb-IV) is safe and feasible (29;34).
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the effects of physical exercise.
The aim of this study is to evaluate the effect of twelve
weeks of a physical and psycho-social program consisting of:
supervised, structured training in a group of advanced lung
cancer patients (cardio and strength training, relaxation
training) twice weekly. Primary outcome is (VO2peak). Our
hypotheses are that patients who undergo this intervention
will increase maximal oxygen uptake (VO2peak), strength
(1RM), functional capacity (6MWD) and quality of life
(HRQOL) and reduce the level of anxiety and depression.
Methods/Design
This randomized controlled trial is being led by the Univer-
sity Hospitals Centre for Health Research at the University
Hospital of Copenhagen, Denmark. The study is supported
by grants from The Center for Integrated Rehabilitation of
Cancer patients (CIRE), a center established and supported
by The Danish Cancer Society and The Novo Nordisk
Foundation. The study is prospectively registered with the
Clinicaltrials.cov; registration number NCT01881906. Eth-
ics approval has been obtained from the scientific Ethics
Review Committee for the Capital Region of DenmarkFigure 1 Study flowchart.(J. HA-2008-06). The study is approved by the Danish Data
protection agency Inspectorate (J. 2008-41-2279). The
Intervention components will be tested on 216 patients
with lung cancer (NSCLC stage IIIb - IV and SCLC ED)
recruited from the lung cancer section at the dept. of oncol-
ogy Copenhagen University Hospital, Rigshospitalet. All
included patients will provide signed informed consent
prior to initiation of any study procedures.
Procedures
Eligible patients >18 years with a WHO performance
status 0–2 with stage IIIb-IV NSCLC and SCLC-ED who
are undergoing chemotherapy at the Department of
Oncology are randomized to standard care or a 12 week
physical and psycho-social intervention (Figure 1). Ran-
domization is stratified for sex and lung cancer type
(NSCLC or SCLC). Randomization is performed by the
Copenhagen Trial Unit (CTU). Exclusion criteria are:
brain or bone metastases; prolonged bone marrow sup-
pression; anti-coagulant treatment; symptomatic heart
disease, including congestive heart failure, arrhythmia or
myocardial infarction diagnosed within the last three
months; and inability to provide informed consent.
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Patients who are randomized to the control group
receive no training but are offered participation in the
supervised training after completion of antineoplastic
treatment, starting no earlier than twelve weeks after
initiation of chemotherapy. Patients in early 2nd line
treatment (“switch maintenance”) will be offered training
after 12 weeks, although they have not necessarily com-
pleted chemotherapy.
Intervention
The supervised training is carried out in groups of 12–16
patients and each session has a duration of 1.5 hours, is
administered twice weekly and is supervised by a research
physiotherapist. The training comprises warm up ex-
ercises, strength and fitness training as well as stretching.
Warm up exercises consist of 10 minutes of light, sta-
tionery cycling, adjusted to 60-90% of the patient’s max-
imum HR. Strength training is carried out using 6
machines (Technogym: Leg press, chest press, lateral ma-
chine, leg extension, abdominal crunch, and lower back).
The practical aim of strength training is to complete 3
series of 5–8 sets, with 70-90% of 1RM. The exercises are
specifically selected to involve the largest possible number
of muscle groups in the least number of exercises. To
ensure progression in strength training, each patient is
instructed in carrying out the 1RM test using each of the
above-mentioned strength training machines once every
second week, after which their program will be adjusted.
Cardiovascular training is carried out as interval training
on stationery bikes. Intensity is equivalent to 85-95%
of each patient’s maximum HR and lasted approximately
10–15 minutes. After the training session, 5–10 minutes
are dedicated to stretching the large muscle groups in
order to increase agility. Following each training session,
progressive relaxation of 15–20 minutes is performed.
Pre training screening
Each patient is screened by a clinical nurse specialist
prior to participating in each physical training session
and before the physiological tests [35]. If one of the fol-
lowing criteria are met, the patient is prohibited from
exercising/being tested on that day: diastolic blood pres-
sure <45 or >95, heart rate (HR) at rest >115/min,
temperature > 38°C, respiratory rate at rest >30/min, in-
fection requiring treatment, fresh bleeding, total leuco-
cyte count <1.0 109/L or platelets <50 109/L. Physical
tests and HRQOL evaluation are performed at baseline
and after six weeks of training.
Study endpoints and assessments
Outcomes will be assessed at baseline (prior to rando-
mization), 12 weeks and 12 months (Table 1). Baseline
assessments involve a medical history; disease andtreatment status is recorded from medical records and
subjects will complete patient reported outcome (PRO)
questionnaires, aerobic capacity (VO2peak (Cardio-Pul-
monary Exercise Test (C-PET)), muscle strength (1RM),
Functional capacity (6 Minute Walk Test (6MWT)).
Primary and secondary endpoints
The primary endpoint will be VO2 peak, as assessed
with an aerobic capacity incremental C-PET on a cycle
ergometer (Monark, ergomedic 839E). The C-PET is
carried out by a physiotherapist who is blinded to the
patient’s study group allocation. The test consists of a
warm-up phase 2–4 minutes of cycling at a sub maximal
load (10–50 watts). After the warm-up period the load
increases after a short break (<2 minutes) by 5–10 watts
every minute, until exhaustion or a possible symptom
limitation (e.g. dizziness, sudden pain, vomiting sen-
sation). Expired gases are analyzed continuously by a
metabolic breath-by-breath analysis and calculated as an
average over 15 seconds using the Oxycon Pro, Jaeger
measurement system. During the C-PET, oxyhemoglobin
saturation and heart rate is continuously monitored.
After each test, maximum ventilation, respiratory ex-
change ratio (RER), possibly plateau in the increase in
VO2, self-perceived exertion perception in the final sec-
onds of the C-PET and maximal heart rate (Polar Team
System 2, Polar, Finland) are recorded. Rating of per-
ceived exertion is evaluated at the end of each workload
using the modified Borg Scale. The primary outcome
will be a comparison of VO2 peak in the intervention
and control arms at the conclusion of the intervention
(i.e. at the 12-week assessment).
Muscle strength is measured by the one repetition max-
imum (1RM) [36] test using a Technogym™ that includes a
leg press (lower extremity), chest press (pectoral muscles),
lateral machine (latissimus dorsi), leg extension (quadriceps
femoris), abdominal crunch (rectus abdominis) and lower
back press (erector spinae). The 1RM test is the golden
standard and has been found to be a reliable assessment to
measure upper and lower extremity strength [36].
Functional capacity is measured by a 6 MWD test.
The test is carried out over a pre-measured distance of
28 meters, in compliance with the American Thoracic
Society (ATS) statement [37]. The 6MWD test has dem-
onstrated good reliability and validity in COPD patients
who are similar to patients with lung cancer with regard
to disease patophysiology and symptomatology [38].
Lung capacity Forced Expiratory Volume in 1 second
(FEV1) is measured using a standard spirometry in a
standing position with the use of the Oxycon Pro, Jaeger
measurement system.
Patient reported Outcomes (PRO’s): PRO’s include stand-
ard validated questionnaires assessing general wellbeing
using the 36-Item Short Form Health Survey (MOS SF-36)
Table 1 Assessments
Physical capacity: Baseline
VO2peak 12 weeks, and 12 months from
the start of the intervention
Muscle strength: Baseline
1RM 12 weeks, and 12 months from
the start of the intervention
Body Composition: Baseline
weight / height, blood
pressure, resting heart rate
12 weeks, and 12 months from
the start of the intervention
Lung function Baseline
Fev1 12 weeks, and 12 months from
the start of the intervention
Socio-demographic Baseline
self-developed 12 weeks, and 12 months from




MSPSS 12 weeks, and 12 months from






12 weeks, and 12 months from
the start of the intervention
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Research and Treatment of Cancer Quality of Life Ques-
tionnaire (EORTC QLG C-30 + LC13) [40] and the FACT
instrument, comprising two parts, i.e. the general part
(FACT-G) and the lung specific part (FACT-L) [41], social
support and network using the Multidimensional Scale of
Perceived Social Support (MSPSS) [42]. Furthermore sleep
quality will be assessed using the Pittsburgh Sleep Quality
Index [43], and levels of anxiety and depression will be
assessed using the Hospital Anxiety and Depression Scale
(HADS) [44]. Additional questionnaires will assess self-
reported physical activity, labour market attachment, work
ability and social reintegration. Demographic data is col-




The sample size calculation for the primary outcome VO2-
peak is based on earlier data [29] in which 55 patients
through six weeks of training achieved an increase of
0.85 ml/kg/min (SD = 2,48 ). It is assumed that patients in
the control group of the current study will have a reduction
of 0.5 ml/kg/min for VO2peak and thus a total of 108 pa-
tients (54 in each arm) will be sufficient to achieve a power
of 80% (risk of type 2 error set at 0.20) using a significance
level of 0.05 (risk of type 1 error set at 0.05). We expect a
drop-out rate of 50% and therefore another 108 patients
must be included yielding a sample size of 216 patients.Data entry is done using OpenClinica and statistical
analysis will be performed using Statistical Analysis Sys-
tems (SAS) version 9.2. The statistician will prepare results
without knowledge of the randomization coding. The pri-
mary endpoint will be reported as a two-sample t-test
comparing change scores in the two randomization
groups. The patient reported outcomes will be reported as
either means with corresponding 95% confidence limits or
as medians interquartile range (IQR) for continuous data.
Categorical data will be reported as proportions and com-
pared across randomization groups using chi-squared
tests. Significance level is set at 0.05.
Discussion
Potential beneficial effects of physical exercise for cancer
patients remains to be demonstrated for lung cancer pa-
tients with advanced disease. Advanced lung cancer is
incurable, and is the leading cause of cancer deaths
world-wide. The aim of the treatment is to improve QoL
and prolong life for these patients, therefore interven-
tions with a focus on VO2peak and functional capacity
are much needed as physical exercise has shown to have
a positive impact on QoL It has been shown [45] that
patients with advanced stage lung cancer significantly
lowered their functional capacity (6 MWD) after two
series of chemotherapy. Moreover, patients with low
functional capacity before starting chemotherapy had
significantly more disease progression and significantly
shorter lifespan, compared to those with a higher func-
tional capacity. Another study [46] supports this result
and found that functional capacity is a strong independ-
ent predictor of survival in advanced NSCLC that adds
to the prediction of survival beyond traditional risk fac-
tors, which may improve risk stratification and prognos-
tication in NSCLC.
Physical exercise for advanced stage lung cancer patients
is a new and unexplored area. The present intervention
has the potential to change standard care with a simple,
safe, relatively inexpensive physical exercise intervention
that could improve the QoL and reduce symptoms and
side effects for patients with advanced stage lung cancer.
This group of patients does not receive curative treatment
and is often not offered meaningful rehabilitation. This
means that, for several months, the patients are not
offered regular exercise despite reduced functional cap-
acity, impaired QOL and burdensome side effects. The
results from this study may help to elucidate any positive
effects of physical exercise during chemotherapy for lung
cancer patients with advanced disease, and whether it is
possible to improve physical capacity and functional level,
in the rehabilitation of cancer patients with complex
symptom burden not receiving treatment with curative
sight, and help them to maintain independent function for
as long as possible.
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The current exercise intervention has already proven to
be safe and feasible for advanced stage lung cancer pa-
tients, with a high completion and adherence rate
(<70%) and of without adverse reactions.
The present randomized controlled study will provide
additional data on the effectiveness of a supervised exer-
cise intervention in patients receiving systemic therapy
for advanced lung cancer, hopefully contributing to an
improvement of the overall treatment results.
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